Axsome Therapeutics, Inc. (AXSM)

Current Report Filed: 2026-04-30

Key Insights

FDA approval of AUVELITY® for agitation associated with dementia due to Alzheimer's disease represents a significant label expansion into the neurodegenerative disease market, potentially opening a new revenue stream beyond the drug's current indications.
This approval demonstrates successful regulatory progress for Axsome's pipeline and validates the company's therapeutic approach, which could enhance investor confidence in future product development efforts.
The expansion into Alzheimer's-related agitation addresses a substantial unmet medical need affecting millions of patients, positioning AUVELITY® as a potential market leader in this indication and supporting long-term revenue growth potential.

Insider Trading Filed: 2026-04-23

Key Insights

Chief Operating Officer Mark Jacobson acquired 8,669 performance stock units (PSUs) on 04/21/2026, representing contingent rights to receive common stock upon achievement of sales and commercial launch milestones.
The PSU grant is milestone-based rather than time-based vesting, indicating the company is tying executive compensation directly to commercial execution and product launch success.
This acquisition by a senior executive at a biotechnology company suggests confidence in upcoming commercial milestones and product launches, though the vesting is contingent on continued service.
The transaction occurred on 04/21/2026 with filing on 04/23/2026, showing standard regulatory compliance with no Rule 10b5-1 trading plan notation, indicating this was likely a routine equity grant rather than discretionary trading.

Insider Trading Filed: 2026-04-23

Key Insights

CEO Herriot Tabuteau acquired 24,081 Performance Stock Units (PSUs) on 04/21/2026, representing contingent rights to common stock that vest upon achievement of sales and commercial launch milestones.
The PSU grant demonstrates management's confidence in Axsome's commercial prospects and ability to hit revenue targets, as vesting is tied to specific sales milestones rather than time-based vesting.
As both Director, 10% Owner, and CEO, Tabuteau's significant equity stake aligns his personal interests with shareholder value creation and successful product commercialization.

Insider Trading Filed: 2026-04-23

Key Insights

Chief Commercial Officer Ari Maizel exercised 7,500 stock options at $70.73 per share and immediately sold all 7,500 shares at an average price of $182.42, realizing a substantial gain of approximately $835,175 or 157% profit within the same day.
The transaction was executed under a pre-approved Rule 10b5-1 trading plan, indicating this was a planned, systematic transaction rather than a reactive market decision, which reduces concerns about negative insider sentiment.
After the sale, Maizel retains 23,710 shares of direct beneficial ownership, demonstrating continued meaningful equity stake in the company despite the full liquidation of this particular option exercise.
The significant gap between the exercise price ($70.73) and sale price ($182.42) suggests substantial stock appreciation since the options were granted, reflecting positive company performance or market conditions.

Insider Trading Filed: 2026-04-23

Key Insights

Chief Commercial Officer Ari Maizel received 7,224 Performance Stock Units (PSUs) on 04/21/2026, contingent upon achievement of sales and commercial launch milestones, indicating confidence in upcoming product commercialization targets.
The PSU grant is tied to specific performance metrics rather than automatic vesting, suggesting management's compensation is directly aligned with company's commercial execution and revenue generation goals.
This executive compensation structure demonstrates the company's focus on near-term commercialization success, particularly relevant given Maizel's role as Chief Commercial Officer overseeing market launch and sales efforts.

Insider Trading Filed: 2026-04-23

Key Insights

CFO Nick Pizzie acquired 8,188 performance stock units (PSUs) on 04/21/2026, representing contingent rights to common shares with $0 exercise price, indicating a compensation award rather than open market purchase.
PSU vesting is contingent upon achievement of sales and commercial launch milestones combined with continued service, suggesting management's compensation is directly tied to commercialization success of company products.
The grant of PSUs to the CFO signals confidence in upcoming revenue-generating milestones and product launches, though the contingent nature means these shares have not yet been earned.

Insider Trading Filed: 2026-04-23

Key Insights

Hunter Murdock, General Counsel of Axsome Therapeutics, acquired 7,224 performance stock units (PSUs) on April 21, 2026, representing a contingent right to receive common shares upon achievement of sales and commercial launch milestones.
The PSU grant is contingent on specific business milestones rather than time-based vesting, indicating management confidence in upcoming product commercialization or sales targets for the company's pipeline.
As General Counsel and an officer, Murdock's acceptance of milestone-based equity compensation suggests alignment with company growth objectives, though the zero upfront value indicates these are future-conditional awards rather than immediate wealth transfers.

Current Report Filed: 2026-04-01

Key Insights

Axsome Therapeutics has acquired a selective PDE10A inhibitor called balipodect, which could potentially be used to treat schizophrenia and other neuropsychiatric conditions.
The acquisition of balipodect represents an expansion of Axsome's pipeline into the neuropsychiatric therapeutic area, diversifying the company's drug development portfolio.
The press release suggests this acquisition is a strategic move by Axsome to bolster its position in the neuropsychiatric drug market and leverage its expertise in central nervous system disorders.

Annual Report Filed: 2026-02-23

Key Insights

Axsome Therapeutics reported strong revenue growth for its products Sunosi and Auvelity, indicating successful commercialization efforts.
The company secured additional financing through term loan agreements, providing capital to support ongoing operations and product development.
Axsome continues to invest in its pipeline, advancing multiple product candidates including AXS-05, AXS-07, and AXS-12, which could drive future growth.

Current Report Filed: 2026-02-23

Key Insights

Axsome Therapeutics announced its financial results for the three months and fiscal year ended December 31, 2025, providing investors with an update on the company's operations.
The company did not disclose any details about material agreements, leadership changes, or earnings surprises in this filing.
Without further details on the financial performance or key business developments, the significance of this 8-K filing is limited.

Current Report Filed: 2026-02-17

Key Insights

Axsome Therapeutics has entered into a settlement agreement with Alkem Laboratories to resolve patent litigation related to its product SUNOSI (solriamfetol). This allows Alkem to sell a generic version of SUNOSI starting in 2040, subject to FDA approval.
The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, indicating regulatory oversight of the deal.
Separate patent litigation related to SUNOSI against another party remains pending, suggesting continued legal uncertainty around the product.

Insider Trading Filed: 2026-02-10

Key Insights

The reporting person, Mark Coleman, exercised 5,193 stock options at $8.02 per share, indicating an increase in his direct ownership of Axsome Therapeutics' common stock.
Coleman also holds 403,856 shares indirectly through an entity over which he has voting and dispositive power, suggesting he maintains a significant ownership stake in the company.
The exercise of options and holding of the underlying shares signals the reporting person's confidence in Axsome Therapeutics' long-term prospects.

Insider Trading Filed: 2026-01-23

Key Insights

The reporting person, Nick Pizzie, who is the Chief Financial Officer of Axsome Therapeutics, Inc., exercised 12,000 stock options and immediately sold the underlying shares for a total transaction value of around $2.25 million.
The transaction was executed pursuant to a pre-approved 10b5-1 trading plan, indicating pre-planned portfolio management rather than a one-off transaction.
The reporting person continues to hold a direct ownership stake of 42,588 shares in the company, in addition to an indirect ownership of 488 shares held in custodial accounts for his children.

Insider Trading Filed: 2026-01-23

Key Insights

Ari Maizel, the Chief Commercial Officer of Axsome Therapeutics, Inc., exercised 7,500 stock options and subsequently sold the same number of shares on January 21, 2026.
The stock option exercise price was $70.73 per share, while the sale price was a weighted average of $184.44 per share, suggesting a significant gain for the reporting person.
This transaction was conducted pursuant to a pre-approved 10b5-1 plan, indicating a planned and structured approach to the insider's trading activity.

Current Report Filed: 2026-01-12

Key Insights

Axsome Therapeutics provided preliminary Q4 and full year 2025 net product revenue figures, indicating continued strong financial performance.
The company did not provide any additional details or commentary on the preliminary results, leaving investors with limited information to assess the significance of the update.
Without further details on product sales, profitability, or guidance, it is difficult to determine the full implications of this announcement for Axsome's future prospects.

Insider Trading Filed: 2026-01-07

Key Insights

Axsome Therapeutics' CEO Herriot Tabuteau exercised and sold a significant number of stock options in early January 2026, indicating insider selling activity.
The sales were executed pursuant to a pre-approved 10b5-1 trading plan, suggesting a planned and systematic liquidation of Tabuteau's equity holdings.
Tabuteau also holds a large indirect beneficial ownership stake in Axsome, suggesting he maintains a substantial economic interest in the company.

Current Report Filed: 2025-12-31

Key Insights

Axsome Therapeutics received FDA acceptance and priority review for its supplemental New Drug Application for the treatment of Alzheimer's Disease Agitation, potentially accelerating the drug's path to market.
The company also received formal pre-NDA meeting minutes from the FDA for its planned NDA submission for AXS-12 in narcolepsy, indicating progress in its pipeline development.
These two key regulatory developments suggest Axsome's pipeline is advancing and could lead to potential new product approvals, which could drive future revenue growth and investor interest.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information